Esperion Therapeutics Inc (NASDAQ:ESPR) major shareholder Target N. V. Biotech purchased 50,000 shares of the stock in a transaction dated Thursday, March 14th. The stock was purchased at an average price of $49.89 per share, with a total value of $2,494,500.00. Following the completion of the acquisition, the insider now directly owns 3,522,964 shares in the company, valued at approximately $175,760,673.96. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
NASDAQ:ESPR traded up $0.84 during midday trading on Friday, reaching $49.87. 891,799 shares of the company traded hands, compared to its average volume of 582,098. Esperion Therapeutics Inc has a twelve month low of $33.06 and a twelve month high of $79.30. The firm has a market capitalization of $1.32 billion, a P/E ratio of -6.61 and a beta of 2.17.
Get Esperion Therapeutics alerts:
A number of hedge funds have recently made changes to their positions in the business. BB Biotech AG boosted its position in Esperion Therapeutics by 3.4% during the 4th quarter. BB Biotech AG now owns 3,392,964 shares of the biopharmaceutical company’s stock worth $156,076,000 after acquiring an additional 110,000 shares during the period. Meditor Group Ltd boosted its position in Esperion Therapeutics by 1.9% during the 4th quarter. Meditor Group Ltd now owns 2,679,835 shares of the biopharmaceutical company’s stock worth $123,272,000 after acquiring an additional 50,000 shares during the period. BlackRock Inc. boosted its position in Esperion Therapeutics by 4.1% during the 3rd quarter. BlackRock Inc. now owns 1,878,905 shares of the biopharmaceutical company’s stock worth $83,367,000 after acquiring an additional 73,673 shares during the period. Vanguard Group Inc boosted its position in Esperion Therapeutics by 6.5% during the 3rd quarter. Vanguard Group Inc now owns 1,649,168 shares of the biopharmaceutical company’s stock worth $73,173,000 after acquiring an additional 99,946 shares during the period. Finally, Vanguard Group Inc. boosted its position in Esperion Therapeutics by 6.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,649,168 shares of the biopharmaceutical company’s stock worth $73,173,000 after acquiring an additional 99,946 shares during the period. Institutional investors own 99.43% of the company’s stock.
ESPR has been the subject of a number of research analyst reports. Needham & Company LLC boosted their price target on Esperion Therapeutics from $94.00 to $114.00 and gave the company a “strong-buy” rating in a report on Monday, January 7th. Stifel Nicolaus boosted their price objective on Esperion Therapeutics from $89.00 to $104.00 and gave the company a “buy” rating in a research report on Monday, December 10th. Goldman Sachs Group initiated coverage on Esperion Therapeutics in a research report on Thursday, December 13th. They set a “sell” rating and a $45.00 price objective for the company. ValuEngine lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 8th. Finally, Cowen restated a “buy” rating and set a $94.00 price objective on shares of Esperion Therapeutics in a research report on Tuesday, January 15th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Esperion Therapeutics has a consensus rating of “Hold” and an average price target of $73.08.
COPYRIGHT VIOLATION WARNING: “Target N. V. Biotech Purchases 50,000 Shares of Esperion Therapeutics Inc (ESPR) Stock” was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at www.tickerreport.com/banking-finance/4224504/target-n-v-biotech-purchases-50000-shares-of-esperion-therapeutics-inc-espr-stock.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Read More: Derivative